BioSpace News Archive

The rising prevalence of neurological disorders across the world is a prime factor boosting the growth of the global wearable brain devices market.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Rising developments in the medical therapy and disease prevention field are estimated to help the global vaccines market to expand at a CAGR of 6% during the forecast period of 2017 to 2025.

The leading players in global surgical display market offer unique and capable solutions for their end users operating in the healthcare and medical industry.

The rise in geriatric population and their vulnerability to various diseases increases hospital visits for proper check-up.

Fact.MR, a market research and competitive intelligence provider: The global self-administered medication market is estimated at USD 87.5 Billion in 2022 and is forecast to surpass USD 200.5 Billion by 2032, growing at a CAGR of 8.6% from 2022 to 2032.

Inmagene Biopharmaceuticals (" Inmagene ") and HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody.

ClearMind Biomedical’s novel neurosurgical endoscope, the Axonpen System, has completed its First in Man clinical trial in Taiwan with outstanding results.

Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, announced a publication in Nature Communications demonstrating that the histone lysine methyltransferase enzyme Suv39h1 plays not only a key role in T cell persistence, but also in T cell activation and exhaustion.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s Biologics License Application and granted Priority Review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that it is voluntarily delisting its shares of common stock from trading on the Tel Aviv Stock Exchange.